| Lastest Insider Transactions Of Enliven Therapeutics, Inc. ( ELVN ) |
| Symbol | Company Name | Insider Name | Title | Date | Transation | Share | Price | Amount | File Date |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-05-14 | Sell | 1,107 | 25.00 | 27,675 | 2024-05-16 19:29:35 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-05-14 | Option Exercise | 1,107 | 2.48 | 2,745 | 2024-05-16 19:29:35 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-05-09 | Sell | 260 | 25.06 | 6,516 | 2024-05-13 19:35:51 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-05-09 | Option Exercise | 260 | 2.48 | 645 | 2024-05-13 19:35:51 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-05-06 | Sell | 4,875 | 22.72 | 110,769 | 2024-05-08 20:40:08 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-05-06 | Option Exercise | 4,875 | 2.48 | 12,090 | 2024-05-08 20:40:08 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-05-03 | Sell | 1,000 | 22.50 | 22,500 | 2024-05-07 18:58:37 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-05-03 | Option Exercise | 1,000 | 2.48 | 2,480 | 2024-05-07 18:58:37 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-04-29 | Sell | 12,000 | 17.92 | 214,988 | 2024-05-01 19:04:07 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-04-29 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-05-01 19:04:07 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-04-29 | Sell | 3,250 | 16.97 | 55,165 | 2024-05-01 19:02:18 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-04-29 | Option Exercise | 3,250 | 2.48 | 8,060 | 2024-05-01 19:02:18 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | PRESIDENT AND CEO | 2024-04-25 | Sell | 12,000 | 16.89 | 202,700 | 2024-04-29 18:50:29 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | PRESIDENT AND CEO | 2024-04-25 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-04-29 18:50:29 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-04-11 | Sell | 17,500 | 25.03 | 438,099 | 2024-04-15 19:06:55 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-04-11 | Option Exercise | 14,903 | 2.48 | 36,959 | 2024-04-15 19:06:55 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-04-11 | Sell | 30,000 | 25.04 | 751,332 | 2024-04-15 19:06:15 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-04-11 | Option Exercise | 30,000 | 1.12 | 33,600 | 2024-04-15 19:06:15 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | PRESIDENT AND CEO | 2024-04-11 | Sell | 47,709 | 25.04 | 1,194,700 | 2024-04-15 19:05:17 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | PRESIDENT AND CEO | 2024-04-11 | Option Exercise | 47,709 | 1.12 | 53,434 | 2024-04-15 19:05:17 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-04-11 | Sell | 14,000 | 24.72 | 346,149 | 2024-04-15 19:04:27 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-04-11 | Option Exercise | 14,000 | 2.48 | 34,720 | 2024-04-15 19:04:27 |
| ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Directior | 2024-04-11 | Sell | 6,964 | 24.11 | 167,888 | 2024-04-15 19:03:32 |
| ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | 2024-04-11 | Sell | 20,000 | 25.07 | 501,478 | 2024-04-15 19:02:46 |
| ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | 2024-04-11 | Option Exercise | 20,000 | 2.48 | 49,600 | 2024-04-15 19:02:46 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-04-10 | Sell | 67,000 | 23.36 | 1,564,812 | 2024-04-12 18:23:49 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-04-10 | Option Exercise | 67,000 | 13.08 | 876,626 | 2024-04-12 18:23:49 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-04-08 | Sell | 4,875 | 18.60 | 90,687 | 2024-04-10 20:35:11 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-04-04 | Sell | 3,485 | 19.15 | 66,729 | 2024-04-08 20:40:47 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-04-04 | Option Exercise | 3,485 | 12.60 | 43,911 | 2024-04-08 20:40:47 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-04-01 | Sell | 3,237 | 19.08 | 61,758 | 2024-04-03 21:32:05 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-04-01 | Option Exercise | 3,237 | 5.73 | 18,534 | 2024-04-03 21:32:05 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-04-01 | Sell | 12,000 | 18.60 | 223,146 | 2024-04-03 21:30:12 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-04-01 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-04-03 21:30:12 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-03-27 | Sell | 3,250 | 18.25 | 59,302 | 2024-03-29 17:59:26 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-03-27 | Option Exercise | 3,250 | 2.48 | 8,060 | 2024-03-29 17:59:26 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | PRESIDENT AND CEO | 2024-03-25 | Sell | 12,000 | 17.56 | 210,661 | 2024-03-27 17:03:00 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | PRESIDENT AND CEO | 2024-03-25 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-03-27 17:03:00 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-03-20 | Sell | 13,278 | 19.16 | 254,462 | 2024-03-22 19:46:23 |
| ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Directior | 2024-03-20 | Option Exercise | 13,278 | 5.52 | 73,295 | 2024-03-22 19:46:23 |
| ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Directior | 2024-03-19 | Sell | 1,270 | 14.50 | 18,419 | 2024-03-21 18:41:07 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-03-06 | Sell | 4,875 | 15.64 | 76,239 | 2024-03-08 19:52:30 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-02-29 | Sell | 12,000 | 16.42 | 197,006 | 2024-03-04 17:55:17 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-02-29 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-03-04 17:55:17 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-02-27 | Sell | 3,250 | 16.97 | 55,163 | 2024-02-29 17:27:02 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-02-27 | Option Exercise | 3,250 | 2.48 | 8,060 | 2024-02-29 17:27:02 |
| ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Directior | 2024-02-15 | Sell | 1,270 | 17.42 | 22,117 | 2024-02-20 19:41:45 |
| ELVN | Enliven Therapeutics, Inc. | 5AM Partners VI, LLC | 10% Owner | 2024-02-14 | Sell | 825,000 | 14.90 | 12,292,500 | 2024-02-16 16:15:31 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | CHIEF OPERATING OFFICER | 2024-02-06 | Sell | 4,875 | 15.11 | 73,658 | 2024-02-08 20:47:50 |
| ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Directior | 2024-01-30 | Sell | 1,270 | 16.41 | 20,840 | 2024-02-01 20:10:19 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-01-29 | Sell | 12,000 | 15.85 | 190,256 | 2024-01-31 21:22:49 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 2024-01-29 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-01-31 21:22:49 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-01-29 | Sell | 3,250 | 15.81 | 51,388 | 2024-01-31 21:20:04 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 2024-01-29 | Option Exercise | 3,250 | 2.48 | 8,060 | 2024-01-31 21:20:04 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2024-01-25 | Sell | 12,000 | 15.69 | 188,230 | 2024-01-29 20:01:22 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2024-01-25 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-01-29 20:01:22 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | Chief Operating Officer | 2024-01-22 | Sell | 4,875 | 15.13 | 73,783 | 2024-01-24 18:38:30 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-12-29 | Sell | 12,000 | 14.28 | 171,381 | 2024-01-03 19:01:58 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-12-29 | Option Exercise | 12,000 | 1.12 | 13,440 | 2024-01-03 19:01:58 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | Chief Operating Officer | 2023-12-28 | Sell | 13,540 | 15.02 | 203,348 | 2024-01-02 20:00:27 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | 2023-12-28 | Sell | 11,870 | 15.02 | 178,327 | 2024-01-02 19:59:41 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | 2023-12-28 | Option Exercise | 11,870 | 2.48 | 29,438 | 2024-01-02 19:59:41 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-12-26 | Sell | 12,000 | 14.64 | 175,709 | 2023-12-28 16:29:27 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-12-26 | Option Exercise | 12,000 | 1.12 | 13,440 | 2023-12-28 16:29:27 |
| ELVN | Enliven Therapeutics, Inc. | Patel Anish | Chief Operating Officer | 2023-12-22 | Sell | 1,085 | 15.03 | 16,306 | 2023-12-27 17:28:02 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | 2023-12-22 | Sell | 1,130 | 15.07 | 17,025 | 2023-12-27 17:26:40 |
| ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Chief Financial Officer | 2023-12-22 | Option Exercise | 1,130 | 2.48 | 2,802 | 2023-12-27 17:26:40 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-12-21 | Sell | 6,566 | 13.07 | 85,790 | 2023-12-26 19:32:17 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-12-21 | Option Exercise | 6,566 | 1.12 | 7,354 | 2023-12-26 19:32:17 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-12-21 | Sell | 8,195 | 13.05 | 106,915 | 2023-12-26 19:31:11 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-12-21 | Option Exercise | 8,195 | 1.12 | 9,178 | 2023-12-26 19:31:11 |
| ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Directior | 2023-12-21 | Sell | 216 | 13.00 | 2,808 | 2023-12-26 19:29:13 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-12-20 | Sell | 7,779 | 13.01 | 101,238 | 2023-12-21 16:31:59 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-12-20 | Option Exercise | 7,779 | 1.12 | 8,712 | 2023-12-21 16:31:59 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-12-19 | Sell | 8,888 | 13.01 | 115,646 | 2023-12-21 16:29:36 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-12-19 | Option Exercise | 8,888 | 1.12 | 9,955 | 2023-12-21 16:29:36 |
| ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Directior | 2023-12-19 | Sell | 4,280 | 13.02 | 55,727 | 2023-12-21 16:28:49 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-11-03 | Sell | 8,546 | 13.08 | 111,751 | 2023-11-06 16:43:09 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-11-03 | Option Exercise | 8,546 | 1.12 | 9,572 | 2023-11-06 16:43:09 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-11-03 | Sell | 8,026 | 13.08 | 104,999 | 2023-11-06 16:42:11 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-11-03 | Option Exercise | 8,026 | 1.12 | 8,989 | 2023-11-06 16:42:11 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-09-29 | Sell | 12,000 | 13.62 | 163,498 | 2023-10-03 19:40:27 |
| ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | 2023-09-29 | Option Exercise | 12,000 | 1.12 | 13,440 | 2023-10-03 19:40:27 |
| ELVN | Enliven Therapeutics, Inc. | 5AM Partners VI, LLC | 10% Owner | 2023-09-26 | Sell | 197,500 | 15.00 | 2,962,500 | 2023-09-28 16:27:26 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-09-25 | Sell | 12,000 | 13.81 | 165,691 | 2023-09-26 19:37:36 |
| ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | President and CEO | 2023-09-25 | Option Exercise | 12,000 | 1.12 | 13,440 | 2023-09-26 19:37:36 |
| ELVN | Enliven Therapeutics, Inc. | 5AM Partners VI, LLC | 10% Owner | 2023-08-24 | Sell | 440,000 | 16.00 | 7,040,000 | 2023-08-28 16:20:16 |
| ELVN | Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC | Directior 10% Owner | 2023-05-17 | Option Exercise | 2,125 | 4.28 | 9,095 | 2023-05-19 16:19:27 |
| ELVN | Enliven Therapeutics, Inc. | Gupta Rishi | Directior 10% Owner | 2023-05-17 | Option Exercise | 2,125 | 4.28 | 9,095 | 2023-05-19 16:12:59 |
| ELVN | Enliven Therapeutics, Inc. | COMMODORE CAPITAL LP | 10% Owner | 2023-02-23 | Buy | 621 | 22.10 | 13,723 | 2023-02-27 17:14:19 |
